Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

(2018) Tarik Asselah et al.   Clinical Gastroenterology and Hepatology

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure

(2018) Fred Poordad et al.   HEPATOLOGY

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

(2018) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients

(2017) Feng Su et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments

(2017) Chung-Feng Huang et al.   EXPERT OPINION ON PHARMACOTHERAPY

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment

(2017) Fred Poordad et al.   HEPATOLOGY

Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients

(2017) Iria Rodríguez-Osorio et al.   JOURNAL OF CLINICAL VIROLOGY

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

(2017) Paul Y. Kwo et al.   JOURNAL OF HEPATOLOGY

Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older

(2017) F. Conti et al.   JOURNAL OF VIRAL HEPATITIS

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

(2017) Xavier Forns et al.   LANCET INFECTIOUS DISEASES

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment

(2017) Edward Gane et al.   NEW ENGLAND JOURNAL OF MEDICINE

The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection

(2016) J. Vermehren et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis

(2016) Edward Gane et al.   GASTROENTEROLOGY

Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

(2016) Sammy Saab et al.   HEPATOLOGY

Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens

(2016) Zobair M. Younossi et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Treatment of Chronic Hepatitis C in the Aged – Does It Impact Life Expectancy? A Decision Analysis

(2016) Yaakov Maor et al.   PLoS One

Hepatitis C Infection in the Elderly

(2015) Sammy Saab et al.   DIGESTIVE DISEASES AND SCIENCES

Pruritus in Kidney Disease

(2015) Sara A. Combs et al.   SEMINARS IN NEPHROLOGY

Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010

(2014) Maxine M. Denniston et al.   ANNALS OF INTERNAL MEDICINE

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

(2014) H. Razavi et al.   JOURNAL OF VIRAL HEPATITIS

Hepatitis C Virus Testing of Persons Born During 1945–1965: Recommendations From the Centers for Disease Control and Prevention

(2013) Bryce D. Smith et al.   ANNALS OF INTERNAL MEDICINE

Changing Trends in Hepatitis C Infection over the Past 50 Years in Japan

(2010) Hobyung Chung et al.   INTERVIROLOGY